CORRECTING and REPLACING Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider
Quantum-Si (Nasdaq: QSI) announces key executive appointments to drive its evolution as a leading proteomic tool provider. Todd Bennett joins as Chief Commercial Officer, bringing over 30 years of experience in life science tools and diagnostics. John Vieceli, Ph.D., is named Chief Product Officer, leveraging his expertise in product development and launch from top DNA sequencing companies. Lindsay Thompson is promoted to Chief Human Resources Officer, recognizing her contributions to company culture and talent management.
These strategic appointments aim to accelerate the global adoption of Quantum-Si's Platinum® technology and enhance product innovation. The company also announced the resignation of Grace Johnston, Ph.D., from her role as Chief Commercial Officer. To facilitate Mr. Bennett's employment, Quantum-Si has authorized Inducement Awards including stock options and restricted stock units, subject to vesting conditions.
Quantum-Si (Nasdaq: QSI) annuncia importanti nomine dirigenziali per guidare la sua evoluzione come fornitore leader di strumenti proteomici. Todd Bennett entra in azienda come Chief Commercial Officer, portando oltre 30 anni di esperienza nel settore degli strumenti per le scienze della vita e della diagnostica. John Vieceli, Ph.D., è stato nominato Chief Product Officer, sfruttando la sua esperienza nello sviluppo e lancio di prodotti in importanti aziende di sequenziamento del DNA. Lindsay Thompson è stata promossa a Chief Human Resources Officer, riconoscendo il suo contributo alla cultura aziendale e alla gestione dei talenti.
Queste nomine strategiche mirano ad accelerare l'adozione globale della tecnologia Platinum® di Quantum-Si e a potenziare l'innovazione dei prodotti. L'azienda ha anche annunciato le dimissioni di Grace Johnston, Ph.D., dal ruolo di Chief Commercial Officer. Per facilitare l'assunzione di Mr. Bennett, Quantum-Si ha autorizzato Inducement Awards che includono opzioni su azioni e unità azionarie con restrizioni, soggette a condizioni di maturazione.
Quantum-Si (Nasdaq: QSI) anuncia nombramientos clave de ejecutivos para impulsar su evolución como un proveedor líder de herramientas proteómicas. Todd Bennett se une como Director Comercial, aportando más de 30 años de experiencia en herramientas para ciencias de la vida y diagnósticos. John Vieceli, Ph.D., es nombrado Director de Productos, aprovechando su experiencia en el desarrollo y lanzamiento de productos en importantes empresas de secuenciación de ADN. Lindsay Thompson es promovida a Directora de Recursos Humanos, reconociendo su contribución a la cultura corporativa y a la gestión del talento.
Estos nombramientos estratégicos tienen como objetivo acelerar la adopción global de la tecnología Platinum® de Quantum-Si y mejorar la innovación de productos. La empresa también anunció la renuncia de Grace Johnston, Ph.D., de su puesto como Directora Comercial. Para facilitar la contratación del Sr. Bennett, Quantum-Si ha autorizado Inducement Awards que incluyen opciones sobre acciones y unidades de acciones restringidas, sujetas a condiciones de adquisición.
Quantum-Si (Nasdaq: QSI)는 주요 경영진 임명을 발표하여 최고의 단백질 분석 도구 제공업체로의 발전을 이끌 것입니다. Todd Bennett는 상업 최고 책임자로 합류하여 생명 과학 도구와 진단 분야에서 30년 이상의 경험을 쌓아왔습니다. John Vieceli, Ph.D.는 제품 개발 및 출시 전문가로 DNA 염기서열 분석 기업에서의 경험을 바탕으로 제품 최고 책임자로 임명되었습니다. Lindsay Thompson은 인사 최고 책임자로 승진하여 회사 문화와 인재 관리에 대한 기여를 인정받았습니다.
이러한 전략적 임명은 Quantum-Si의 Platinum® 기술의 글로벌 채택을 가속화하고 제품 혁신을 강화하는 것을 목표로 합니다. 회사는 또한 Grace Johnston, Ph.D.가 상업 최고 책임자 직에서 사임했음을 발표했습니다. Bennett 씨의 고용을 촉진하기 위해 Quantum-Si는 조건부로 스톡 옵션과 제한 주식 단위를 포함하는 Inducement Awards를 승인했습니다.
Quantum-Si (Nasdaq: QSI) annonce des nominations clés au sein de sa direction pour faire évoluer son statut de fournisseur leader d'outils protéomiques. Todd Bennett rejoint l'entreprise en tant que Directeur Commercial, apportant plus de 30 ans d'expérience dans les outils de sciences de la vie et le diagnostic. John Vieceli, Ph.D., est nommé Directeur Produit, s'appuyant sur son expertise dans le développement et le lancement de produits dans des entreprises de séquençage ADN de premier plan. Lindsay Thompson est promue au poste de Directrice des Ressources Humaines, reconnaissant ses contributions à la culture d'entreprise et à la gestion des talents.
Ces nominations stratégiques visent à accélérer l'adoption mondiale de la technologie Platinum® de Quantum-Si et à améliorer l'innovation produit. L'entreprise a également annoncé la démission de Grace Johnston, Ph.D., de son poste de Directrice Commerciale. Pour faciliter l'embauche de M. Bennett, Quantum-Si a autorisé des Inducement Awards, comprenant des options d'actions et des unités d'actions restreintes, sous réserve de conditions d'acquisition.
Quantum-Si (Nasdaq: QSI) gibt wichtige Ernennungen im Management bekannt, um seine Entwicklung als führender Anbieter von proteomischen Werkzeugen voranzutreiben. Todd Bennett wird Chief Commercial Officer und bringt über 30 Jahre Erfahrung im Bereich Lebenswissenschaften und Diagnostik mit. John Vieceli, Ph.D., wird Chief Product Officer und nutzt seine Expertise in der Produktentwicklung und -einführung aus führenden DNA-Sequenzierungsunternehmen. Lindsay Thompson wird zur Chief Human Resources Officer befördert, was ihren Beitrag zur Unternehmenskultur und Talentmanagement anerkennt.
Diese strategischen Ernennungen zielen darauf ab, die globale Verbreitung der Platinum®-Technologie von Quantum-Si zu beschleunigen und die Produktinnovation zu verbessern. Das Unternehmen kündigte ebenfalls den Rücktritt von Grace Johnston, Ph.D., von ihrer Position als Chief Commercial Officer an. Um die Anstellung von Herrn Bennett zu erleichtern, hat Quantum-Si Inducement Awards genehmigt, die Aktienoptionen und beschränkte Aktieneinheiten umfassen, die an Vesting-Bedingungen geknüpft sind.
- None.
- None.
The updated release reads:
QUANTUM-SI ANNOUNCES NEW EXECUTIVE TEAM MEMBERS TO ACCELERATE THE EVOLUTION OF THE COMPANY INTO A LEADING PROTEOMIC TOOL PROVIDER
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that Todd Bennett will join QSI as the Company’s new Chief Commercial Officer effective September 17, 2024, John Vieceli, Ph.D. has been named Chief Product Officer and Lindsay Thompson has been named Chief Human Resources Officer.
“I am pleased to welcome Todd to QSI as we look to leverage his breadth of industry experience to accelerate the global adoption of Platinum®. Todd is a highly regarded commercial leader in our industry and his track record of building high performing commercial teams and driving market adoption of new technologies is perfectly aligned with our needs for the next phase in the commercialization of our Next-Generation Protein Sequencing™ technology,” said Jeff Hawkins, Chief Executive Officer of Quantum-Si.
Mr. Bennett brings over 30 years of commercial leadership experience in life science tools and diagnostics to Quantum-Si. He brings expertise in building and leading teams across sales, marketing, customer service, business development, and strategy. Mr. Bennett has worked at industry leaders such as Luminex, Abbott, Roche and Immucor. Mr. Bennett holds a B.S. degree in Business Administration with an emphasis in finance from the Max M. Fisher College of Business at Ohio State University.
“The implementation of the role of Chief Product Officer will integrate all activities from product development through to production and delivery to customers. We are seeing continued acceleration across all our innovation roadmaps and this new role enhances our ability to continue to deliver new products on time and with the highest quality to our customers. John has been instrumental in the launch of 2 new sequencing kits and multiple new software analysis tools over the past year and his product development and launch experience from leading life sciences companies makes him the ideal person to lead the product organization going forward,” said Mr. Hawkins.
Dr. Vieceli joined Quantum-Si in December of 2022 and prior to that has held leadership roles at top DNA sequencing companies, including Illumina, Omniome, and Pacific Biosciences, focusing on bioinformatics, signal processing, and computer subsystems. At Illumina, he received the 2022 Annual Innovation Award for advancements in signal processing that boosted sequencing accuracy. He is an inventor on over 25 issued patents and pending applications and has authored more than 20 scientific publications. Dr. Vieceli earned his Ph.D. in Theoretical Physical Chemistry from UC Santa Cruz and his B.S. in Biology and Chemistry from Santa Clara University.
“The success of Quantum-Si is driven by the talented people who work here and the Company culture that underpins how we work together every day. Lindsay has been the driving force behind these initiatives for the past four years and this promotion recognizes that contribution and serves as the logical next step in the Company’s growth and development,” said Mr. Hawkins.
Ms.
Finally, Grace Johnston, PhD., has resigned from her role as Chief Commercial Officer. Dr. Johnston will provide transitional support to the Company through September 6, 2024. The Company would like to thank Dr. Johnston for her contributions to Quantum-Si during her tenure.
Inducement Awards
Subject to Mr. Bennett commencing employment, the Compensation Committee of the Company’s Board of Directors, among other things, authorized the grant to Mr. Bennett on his start date of (i) stock options to purchase shares of the Company’s Class A common stock having an aggregate grant date fair value of
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum™ protein sequencing instrument and kits and the Company’s other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827690470/en/
Investor Contact
Doug Farrell, VP, Investor Relations
ir@quantum-si.com
Media Contact
Katherine Atkinson, SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
Who are the new executive team members at Quantum-Si (QSI)?
What is Todd Bennett's role at Quantum-Si (QSI) and when does he start?
What is Quantum-Si's (QSI) main product mentioned in the announcement?
What are the Inducement Awards offered to Todd Bennett by Quantum-Si (QSI)?
Who has resigned from Quantum-Si (QSI) and what was their role?
